RAPT Therapeutics
| General Information | |
| Business: |
We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing our proprietary drug discovery and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 94 |
| Founded: | 2015 |
| Contact Information | |
| Address | 561 Eccles Avenue South San Francisco, CA 94080, US |
| Phone Number | (650) 489-9000 |
| Web Address | http://www.rapt.com |
| View Prospectus: | RAPT Therapeutics |
| Financial Information | |
| Market Cap | $255.3mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-39.5 mil (last 12 months) |
| IPO Profile | |
| Symbol | RAPT |
| Exchange | NASDAQ |
| Shares (millions): | 3.0 |
| Price range | $12.00 - $12.00 |
| Est. $ Volume | $36.0 mil |
| Manager / Joint Managers | BMO Capital Markets/ Wells Fargo Securities/ UBS Investment Bank |
| CO-Managers | - |
| Expected To Trade: | 10/31/2019 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |